Contrast, motion, perceptual integration, and neurocognition in schizophrenia

The role of fragile-X related mechanisms

O. Kelemen, Tamás Kovács, S. Kéri

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Recent studies demonstrated a reduced expression of Fragile X Mental Retardation Protein (FMRP), an RNA binding protein and translation regulator, in the brain and peripheral lymphocytes of patients with schizophrenia. Low FMRP levels may be related to impaired neurodevelopmental processes and synaptic plasticity. Here, we studied the relationship between peripheral FMRP level, visual perception (contrast sensitivity, perceptual integration, motion/form perception), and neuropsychological functions in schizophrenia as measured with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Results revealed that patients with schizophrenia displayed lower FMRP levels in peripheral lymphocytes as compared to control individuals. We found significant correlations between FMRP levels and contrast sensitivity at low spatial and high temporal frequencies, perceptual integration, and motion perception. The relationship between FMRP level and neuropsychological functions was less pronounced than that seen in the case of visual perception, with the greatest effect for RBANS attention. FMRP level was not related to contrast sensitivity at high spatial and low temporal frequencies and form perception. This pattern of data is reminiscent to that observed in patients with Fragile X Syndrome (FXS). These results suggest that FMRP may be implicated in the pathogenesis of schizophrenia, possibly via the regulation of neurodevelopment, plasticity, GABA-ergic, and glutamatergic neurotransmission.

Original languageEnglish
Pages (from-to)92-97
Number of pages6
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume46
DOIs
Publication statusPublished - Oct 1 2013

Fingerprint

Fragile X Mental Retardation Protein
Schizophrenia
Contrast Sensitivity
Form Perception
Motion Perception
Visual Perception
Lymphocytes
Time Perception
Fragile X Syndrome
Neuronal Plasticity
RNA-Binding Proteins
Protein Biosynthesis
Protein Binding
Synaptic Transmission
gamma-Aminobutyric Acid

Keywords

  • Fragile X Syndrome
  • Neurocognition
  • Schizophrenia
  • Visual perception

ASJC Scopus subject areas

  • Biological Psychiatry
  • Pharmacology

Cite this

@article{4a4a73d5bce845b698953a559f1076d4,
title = "Contrast, motion, perceptual integration, and neurocognition in schizophrenia: The role of fragile-X related mechanisms",
abstract = "Recent studies demonstrated a reduced expression of Fragile X Mental Retardation Protein (FMRP), an RNA binding protein and translation regulator, in the brain and peripheral lymphocytes of patients with schizophrenia. Low FMRP levels may be related to impaired neurodevelopmental processes and synaptic plasticity. Here, we studied the relationship between peripheral FMRP level, visual perception (contrast sensitivity, perceptual integration, motion/form perception), and neuropsychological functions in schizophrenia as measured with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Results revealed that patients with schizophrenia displayed lower FMRP levels in peripheral lymphocytes as compared to control individuals. We found significant correlations between FMRP levels and contrast sensitivity at low spatial and high temporal frequencies, perceptual integration, and motion perception. The relationship between FMRP level and neuropsychological functions was less pronounced than that seen in the case of visual perception, with the greatest effect for RBANS attention. FMRP level was not related to contrast sensitivity at high spatial and low temporal frequencies and form perception. This pattern of data is reminiscent to that observed in patients with Fragile X Syndrome (FXS). These results suggest that FMRP may be implicated in the pathogenesis of schizophrenia, possibly via the regulation of neurodevelopment, plasticity, GABA-ergic, and glutamatergic neurotransmission.",
keywords = "Fragile X Syndrome, Neurocognition, Schizophrenia, Visual perception",
author = "O. Kelemen and Tam{\'a}s Kov{\'a}cs and S. K{\'e}ri",
year = "2013",
month = "10",
day = "1",
doi = "10.1016/j.pnpbp.2013.06.017",
language = "English",
volume = "46",
pages = "92--97",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Contrast, motion, perceptual integration, and neurocognition in schizophrenia

T2 - The role of fragile-X related mechanisms

AU - Kelemen, O.

AU - Kovács, Tamás

AU - Kéri, S.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - Recent studies demonstrated a reduced expression of Fragile X Mental Retardation Protein (FMRP), an RNA binding protein and translation regulator, in the brain and peripheral lymphocytes of patients with schizophrenia. Low FMRP levels may be related to impaired neurodevelopmental processes and synaptic plasticity. Here, we studied the relationship between peripheral FMRP level, visual perception (contrast sensitivity, perceptual integration, motion/form perception), and neuropsychological functions in schizophrenia as measured with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Results revealed that patients with schizophrenia displayed lower FMRP levels in peripheral lymphocytes as compared to control individuals. We found significant correlations between FMRP levels and contrast sensitivity at low spatial and high temporal frequencies, perceptual integration, and motion perception. The relationship between FMRP level and neuropsychological functions was less pronounced than that seen in the case of visual perception, with the greatest effect for RBANS attention. FMRP level was not related to contrast sensitivity at high spatial and low temporal frequencies and form perception. This pattern of data is reminiscent to that observed in patients with Fragile X Syndrome (FXS). These results suggest that FMRP may be implicated in the pathogenesis of schizophrenia, possibly via the regulation of neurodevelopment, plasticity, GABA-ergic, and glutamatergic neurotransmission.

AB - Recent studies demonstrated a reduced expression of Fragile X Mental Retardation Protein (FMRP), an RNA binding protein and translation regulator, in the brain and peripheral lymphocytes of patients with schizophrenia. Low FMRP levels may be related to impaired neurodevelopmental processes and synaptic plasticity. Here, we studied the relationship between peripheral FMRP level, visual perception (contrast sensitivity, perceptual integration, motion/form perception), and neuropsychological functions in schizophrenia as measured with the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS). Results revealed that patients with schizophrenia displayed lower FMRP levels in peripheral lymphocytes as compared to control individuals. We found significant correlations between FMRP levels and contrast sensitivity at low spatial and high temporal frequencies, perceptual integration, and motion perception. The relationship between FMRP level and neuropsychological functions was less pronounced than that seen in the case of visual perception, with the greatest effect for RBANS attention. FMRP level was not related to contrast sensitivity at high spatial and low temporal frequencies and form perception. This pattern of data is reminiscent to that observed in patients with Fragile X Syndrome (FXS). These results suggest that FMRP may be implicated in the pathogenesis of schizophrenia, possibly via the regulation of neurodevelopment, plasticity, GABA-ergic, and glutamatergic neurotransmission.

KW - Fragile X Syndrome

KW - Neurocognition

KW - Schizophrenia

KW - Visual perception

UR - http://www.scopus.com/inward/record.url?scp=84880938430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880938430&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2013.06.017

DO - 10.1016/j.pnpbp.2013.06.017

M3 - Article

VL - 46

SP - 92

EP - 97

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

ER -